Molecular docking-guided design, synthesis, and biological evaluation of novel multitarget HDAC/ROCK inhibitors
Authors: Beljkas, Milan; Zukic, Selma; Mirjacic Martinovic, Katarina; Djuric, Ana; Vuletic, Ana; Jallet, Corinne; Holzel, Julia; Bottger, Elias; Gajic, Mihajlo; Zivanovic, Marija; Santibanez, Juan F; Stark, Holger; Zivkovic, Aleksandra; Srdic-Rajic, Tatjana; Arimondo, Paola; Maran, Uko; Nikolic, Katarina; Petkovic, Milos; Oljacic, Slavica
Source journal: RSC medicinal chemistry (2026-11-03)
DOI: 10.1039/d6md00613b
Abstract
Histone deacetylases (HDACs) and Rho-associated coiled-coil containing protein kinases (ROCKs) play key roles in tumor progression, metastasis, and immunomodulation, particularly in aggressive malignancies such as triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC). Previous in silico and in vitro studies demonstrated the therapeutic promise of dual HDAC/ROCK inhibition and led to the identification of C-9 as the first-in-class multitarget HDAC/ROCK inhibitor and the lead compound of this study. Using a structure-based drug design (SBDD) approach, a novel series of multitarget HDAC/ROCK inhibitors was developed and synthesized. Among them, compounds C-35 and C-40 exhibited pronounced cytotoxicity, surpassing the reference selective HDAC6 and ROCK inhibitors tubastatin A and fasudil. Both compounds induced early apoptosis, caused cell-cycle arrest, and reduced PD-L1 expression. Furthermore, C-35 and C-40 demonstrated significant anti-migratory and anti-invasive effects in TNBC cell lines. Microsomal stability studies revealed sex-dependent metabolic differences for C-40, which showed lower stability and approximately fourfold higher in vitro clearance in female compared to male microsomes. In contrast, C-35 exhibited favorable microsomal stability in both male and female human liver microsomes, with only a modest 1.2-fold faster metabolism in females. Overall, this study highlights the therapeutic potential of multitarget HDAC/ROCK inhibition and establishes a robust computational-experimental approach for future inhibitor development.
Related topics
Related open access articles
- Development and Validation Molecular Docking Analysis of Human serum albumin (HSA)
- Facing COVID-19 via anti-inflammatory mechanism of action: Molecular docking and Pharmacokinetic studies of six anti-inflammatory compounds derived from Passiflora edulis
- Computational analysis by molecular docking of thirty alkaloid compounds from medicinal plants as potent inhibitors of SARS-CoV-2 main protease
- Curcumin and pipernonaline to curb diabetes the natural way: A molecular modeling, docking and dynamics simulation study
- DENSITY FUNCTIONAL THEORY ANALYSIS AND MOLECULAR DOCKING EVALUATION OF 8-CHLOROQUINOLINE 2-CARBALDEHYDE
- Thermochemical, DFT, Molecular Docking and Pharmacokinetic Studies of Methyl β-D-galactopyranoside Esters
Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.